10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TWEAK Antibody
Catalog # ASC10414

Specification

TWEAK Antibody - Product Information

Application	**IF, IHC**
Primary Accession	O43508
Other Accession	NP_003800, 8742
Reactivity	**Human, Mouse, Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**IgG**
Calculated MW	**Predicted: 27 kDa KDa**
Application Notes	**TWEAK antibody can be used for the detection of TWEAK by Western blot at 1 to 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.**

TWEAK Antibody - Additional Information

Gene ID **8742**

Other Names
TWEAK Antibody: APO3L, DR3LG, TWEAK, APO3L, UNQ181/PRO207, Tumor necrosis factor ligand superfamily member 12, APO3 ligand, tumor necrosis factor (ligand) superfamily, member 12

Target/Specificity
TWEAK antibody was raised against recombinant human TWEAK protein.

Reconstitution & Storage
TWEAK antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Precautions
TWEAK Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

TWEAK Antibody - Protein Information

Name TNFSF12

Synonyms APO3L, DR3LG

Function
Binds to FN14 and possibly also to TNRFSF12/APO3. Weak inducer of apoptosis in some cell types. Mediates NF-kappa-B activation. Promotes angiogenesis and the proliferation of endothelial cells. Also involved in induction of inflammatory cytokines. Promotes IL8 secretion.

Cellular Location
Cell membrane; Single-pass type II membrane protein [Isoform TWE-PRIL]: Cell membrane; Single-pass membrane protein

Tissue Location
Highly expressed in adult heart, pancreas, skeletal muscle, brain, colon, small intestine, lung, ovary, prostate, spleen, lymph node, appendix and peripheral blood lymphocytes. Low expression in kidney, testis, liver, placenta, thymus and bone marrow. Also detected in fetal kidney, liver, lung and brain

TWEAK Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

TWEAK Antibody - Images



Immunofluorescence of BACE in 3T3 cells with BACE antibody at 20 µg/ml.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999



Immunohistochemistry of CD4 in human thymus tissue with CD4 antibody at 5 µg/ml.

TWEAK Antibody - Background

TWEAK Antibody: TNF-related weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily (TNFSF) of structurally related cytokines. Like most other members of this family, TWEAK is a cell surface-associated type II transmembrane protein although a smaller, biologically active form can also be generated by cleavage near the cell membrane. TWEAK has multiple biological activities, including stimulation of cell growth and angiogenesis, induction of inflammatory cytokines, in addition to stimulation of apoptosis. The TWEAK signal transduction pathway has not been well established but it appears to signal via TweakR/Fn14 in a manner similar to that described for other TNFSF members that bind receptors lacking death domains.

TWEAK Antibody - References

Wiley SR and Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cyto. And Growth Factor Rev. 2003; 14:241-9.
Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 1997; 272:32401-10.
Lynch CN, Wang YC, Lund JK, et al. TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 1999; 274:8455-9.
Chicheportiche Y, Chicheportiche R, Sizing I, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthr. Res. 2002; 4:126-33. 5.